Gilead Sciences Inc (GILD)
64.78
-0.55
(-0.84%)
USD |
NASDAQ |
May 03, 16:00
64.80
+0.02
(+0.03%)
After-Hours: 07:08
Gilead Sciences SG&A Expense (TTM): 6.147B for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 6.147B |
December 31, 2023 | 6.091B |
September 30, 2023 | 6.503B |
June 30, 2023 | 6.401B |
March 31, 2023 | 5.909B |
December 31, 2022 | 5.673B |
September 30, 2022 | 5.303B |
June 30, 2022 | 5.28B |
March 31, 2022 | 5.274B |
December 31, 2021 | 5.246B |
September 30, 2021 | 5.326B |
June 30, 2021 | 5.242B |
March 31, 2021 | 5.13B |
December 31, 2020 | 5.151B |
September 30, 2020 | 4.625B |
June 30, 2020 | 4.571B |
March 31, 2020 | 4.427B |
December 31, 2019 | 4.381B |
September 30, 2019 | 4.308B |
June 30, 2019 | 4.204B |
March 31, 2019 | 4.089B |
December 31, 2018 | 4.056B |
September 30, 2018 | 4.177B |
June 30, 2018 | 4.108B |
March 31, 2018 | 4.025B |
Date | Value |
---|---|
December 31, 2017 | 3.878B |
September 30, 2017 | 3.618B |
June 30, 2017 | 3.57B |
March 31, 2017 | 3.563B |
December 31, 2016 | 3.398B |
September 30, 2016 | 3.472B |
June 30, 2016 | 3.544B |
March 31, 2016 | 3.466B |
December 31, 2015 | 3.426B |
September 30, 2015 | 3.236B |
June 30, 2015 | 3.278B |
March 31, 2015 | 3.08B |
December 31, 2014 | 2.983B |
September 30, 2014 | 2.620B |
June 30, 2014 | 2.082B |
March 31, 2014 | 1.873B |
December 31, 2013 | 1.699B |
September 30, 2013 | 1.552B |
June 30, 2013 | 1.465B |
March 31, 2013 | 1.392B |
December 31, 2012 | 1.461B |
September 30, 2012 | 1.441B |
June 30, 2012 | 1.418B |
March 31, 2012 | 1.390B |
December 31, 2011 | 1.242B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
4.204B
Minimum
Jun 2019
6.503B
Maximum
Sep 2023
5.260B
Average
5.26B
Median
SG&A Expense (TTM) Benchmarks
Amgen Inc | 6.729B |
CymaBay Therapeutics Inc (DELISTED) | 51.95M |
Bristol-Myers Squibb Co | 8.377B |
Eli Lilly and Co | 6.912B |
Xilio Therapeutics Inc | 27.00M |